- Home
- MREO vs AQST Comparison
MREO vs AQST Comparison
Compare MREO & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- AQST
- Stock Information
- Founded
- MREO 2015
- AQST 2004
- Country
- MREO United Kingdom
- AQST United States
- Employees
- MREO N/A
- AQST N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- MREO Health Care
- AQST Health Care
- Exchange
- MREO Nasdaq
- AQST Nasdaq
- Market Cap
- MREO 577.6M
- AQST 502.6M
- IPO Year
- MREO N/A
- AQST 2018
- Fundamental
- Price
- MREO $3.68
- AQST $4.51
- Analyst Decision
- MREO Strong Buy
- AQST Strong Buy
- Analyst Count
- MREO 4
- AQST 7
- Target Price
- MREO $7.50
- AQST $9.43
- AVG Volume (30 Days)
- MREO 769.7K
- AQST 1.7M
- Earning Date
- MREO 11-12-2024
- AQST 11-04-2024
- Dividend Yield
- MREO N/A
- AQST N/A
- EPS Growth
- MREO N/A
- AQST N/A
- EPS
- MREO N/A
- AQST N/A
- Revenue
- MREO $1,000,000.00
- AQST $58,900,000.00
- Revenue This Year
- MREO $16.39
- AQST $18.45
- Revenue Next Year
- MREO $9.44
- AQST N/A
- P/E Ratio
- MREO N/A
- AQST N/A
- Revenue Growth
- MREO N/A
- AQST 22.56
- 52 Week Low
- MREO $1.86
- AQST $1.84
- 52 Week High
- MREO $5.02
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- MREO 39.84
- AQST 40.86
- Support Level
- MREO $3.18
- AQST $4.36
- Resistance Level
- MREO $4.40
- AQST $4.88
- Average True Range (ATR)
- MREO 0.24
- AQST 0.37
- MACD
- MREO -0.06
- AQST -0.07
- Stochastic Oscillator
- MREO 41.39
- AQST 12.20
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.